Literature DB >> 17401528

Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression.

S Anttila1, K Huuhka, M Huuhka, R Rontu, M Hurme, E Leinonen, T Lehtimäki.   

Abstract

Several studies have linked 5-HT1A C1019G and BDNF G196A (Val66Met) gene polymorphisms to major depressive disorder (MDD) and the actions of antidepressants. We attempt to show that the interaction between 5-HT1A and BDNF polymorphism predicts the risk of treatment-resistant depression. The sample consists of 119 patients with treatment-resistant MDD and 392 controls. 5-HT1A C1019G and BDNF G196A (Val66Met) polymorphisms were studied. The combination of 5-HT1A GG and BDNF GA + AA genotypes is associated with an increased risk of depression.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17401528     DOI： 10.1007/s00702-007-0705-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  24 in total

Review 1.  Diagnosis and definition of treatment-resistant depression.

Authors:  Maurizio Fava
Journal:  Biol Psychiatry       Date:  2003-04-15       Impact factor: 13.382

Review 2.  Is treatment-resistant depression a unique subtype of depression?

Authors:  Andrea Fagiolini; David J Kupfer
Journal:  Biol Psychiatry       Date:  2003-04-15       Impact factor: 13.382

Review 3.  A neurotrophic model for stress-related mood disorders.

Authors:  Ronald S Duman; Lisa M Monteggia
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

4.  Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study.

Authors:  Ramin V Parsey; Maria A Oquendo; R Todd Ogden; Doreen M Olvet; Norman Simpson; Yung-Yu Huang; Ronald L Van Heertum; Victoria Arango; J John Mann
Journal:  Biol Psychiatry       Date:  2005-09-09       Impact factor: 13.382

5.  The apolipoprotein E polymorphism is not associated with response to electroconvulsive therapy in major depressive disorder.

Authors:  Martti Huuhka; Sami Anttila; Esa Leinonen; Kaija Huuhka; Riikka Rontu; Kari M Mattila; Heini Huhtala; Terho Lehtimäki
Journal:  J ECT       Date:  2005-03       Impact factor: 3.635

6.  No implication of brain-derived neurotrophic factor (BDNF) gene in unipolar affective disorder: evidence from Belgian first and replication patient-control studies.

Authors:  Pierre Oswald; Jurgen Del-Favero; Isabelle Massat; Daniel Souery; Stephan Claes; Christine Van Broeckhoven; Julien Mendlewicz
Journal:  Eur Neuropsychopharmacol       Date:  2005-04-01       Impact factor: 4.600

7.  BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects.

Authors:  Xueying Jiang; Ke Xu; Joelle Hoberman; Feng Tian; Aimee J Marko; Juwaria F Waheed; Claudia R Harris; Ann M Marini; Mary-Anne Enoch; Robert H Lipsky
Journal:  Neuropsychopharmacology       Date:  2005-07       Impact factor: 7.853

8.  Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T are not associated with response to electroconvulsive therapy in major depressive disorder.

Authors:  Kaija Huuhka; Sami Anttila; Martti Huuhka; Esa Leinonen; Riikka Rontu; Kari Mattila; Terho Lehtimäki
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-02       Impact factor: 5.270

9.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

10.  The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.

Authors:  Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger
Journal:  Cell       Date:  2003-01-24       Impact factor: 41.582
View more
  32 in total

Review 1.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

Review 2.  Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: the 5-HT1A receptor gene as a paradigm

Authors:  Paul R. Albert; Brice Le François; Faranak Vahid-Ansari
Journal:  J Psychiatry Neurosci       Date:  2019-05-01       Impact factor: 6.186

Review 3.  5-HT(1A) receptor function in major depressive disorder.

Authors:  Jonathan Savitz; Irwin Lucki; Wayne C Drevets
Journal:  Prog Neurobiol       Date:  2009-02-07       Impact factor: 11.685

Review 4.  Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

Authors:  George Anderson; Michael Berk; Olivia Dean; Steven Moylan; Michael Maes
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

5.  The serotonin 1A receptor gene in mood disorders: a tale of missed opportunities.

Authors:  Philipp G Sand
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-11-20       Impact factor: 5.270

Review 6.  The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy.

Authors:  M Notaras; R Hill; M van den Buuse
Journal:  Mol Psychiatry       Date:  2015-03-31       Impact factor: 15.992

Review 7.  5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function.

Authors:  Alvaro L Garcia-Garcia; Adrian Newman-Tancredi; E David Leonardo
Journal:  Psychopharmacology (Berl)       Date:  2013-12-12       Impact factor: 4.530

8.  Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy.

Authors:  Paul R Albert; Brice Le François
Journal:  Front Neurosci       Date:  2010-06-17       Impact factor: 4.677

9.  Pharmacogenetics studies in STAR*D: strengths, limitations, and results.

Authors:  Gonzalo Laje; Roy H Perlis; A John Rush; Francis J McMahon
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

10.  Additive genetic risk from five serotonin system polymorphisms interacts with interpersonal stress to predict depression.

Authors:  Suzanne Vrshek-Schallhorn; Catherine B Stroud; Susan Mineka; Richard E Zinbarg; Emma K Adam; Eva E Redei; Constance Hammen; Michelle G Craske
Journal:  J Abnorm Psychol       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.